A detailed history of Mariner, LLC transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Mariner, LLC holds 16,081 shares of DSGN stock, worth $118,516. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,081
Previous 15,740 2.17%
Holding current value
$118,516
Previous $53,000 128.3%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$3.52 - $7.53 $1,200 - $2,567
341 Added 2.17%
16,081 $121,000
Q2 2025

Aug 14, 2025

BUY
$2.79 - $4.86 $750 - $1,307
269 Added 1.74%
15,740 $53,000
Q1 2025

May 15, 2025

SELL
$3.68 - $6.66 $2,892 - $5,234
-786 Reduced 4.83%
15,471 $59,000
Q4 2024

Feb 13, 2025

BUY
$4.56 - $7.5 $588 - $967
129 Added 0.8%
16,257 $100,000
Q3 2024

Nov 13, 2024

SELL
$3.19 - $5.88 $8,121 - $14,970
-2,546 Reduced 13.63%
16,128 $86,000
Q1 2024

May 15, 2024

BUY
$2.27 - $4.03 $42,389 - $75,256
18,674 New
18,674 $75,000

Others Institutions Holding DSGN

About Design Therapeutics, Inc.


  • Ticker DSGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,807,900
  • Market Cap $411M
  • Description
  • Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...
More about DSGN
Track This Portfolio

Track Mariner, LLC Portfolio

Follow Mariner, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.